Fairvalue-Calculator Fairvalue-Calculator
EN DE

MegaPro Biomedical Co (6827) Fair Value & Analysis

Healthcare · TW · Market cap 952M TWD

Price12.90 TWD
Fair Value9.93 TWD
Upside-23.0%
Quality95/100
Evidence: Low Range 7.45 TWD – 12.42 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

MegaPro Biomedical Co (6827) currently trades at 12.90 TWD, while our model-based Fair Value estimate is 9.93 TWD — implying the stock looks roughly 23.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is MegaPro Biomedical Co (6827) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 9.93 TWD versus a price of 12.90 TWD — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6827?
Our 21-model fair value for MegaPro Biomedical Co is 9.93 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 12.90 TWD.
What is the quality score of 6827?
MegaPro Biomedical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.